Early brain radiotherapy combined with third-generation EGFR-TKIs improves survival in EGFR-mutant NSCLC with synchronous brain metastases: a multi-center retrospective analysis
{{output}}
Objective: The optimal timing for combining brain radiotherapy with first-line third-generation EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutant non-small cell lung cancer (NSCLC) and synchronous brain metastas... ...
